The University of California, Los Angeles (UCLA), under its Office of Research Administration, received a $157,473 Project Grant award from the Defense Health Agency (DHA) on May 1, 2024 to conduct research for the "TESTING UCHL1 AS A NEW MINIMALLY INVASIVE BIOMARKER AND THERAPEUTIC TARGET FOR NEUROENDOCRINE PROSTATE CANCER" project. This award is funded through the DHA's Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military personnel, veterans, and the public. The project will investigate the potential of UCHL1 as a new biomarker and therapeutic target for neuroendocrine prostate cancer, with an anticipated completion date of April 30, 2026. As a prime grantee, UCLA will leverage its research expertise, facilities, and partnerships to carry out this scientific study addressing an important medical challenge relevant to the military community.
Generated 1/28/25, 10:02 AM